Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1099 - 1104
Section II - La réalité clinique
DOI https://doi.org/10.1051/medsci/200925121099
Publié en ligne 15 décembre 2009
  1. Folkman J.Tumor angiogenesis : therapeutic implications. N Engl J Med 1971; 285 : 1182–6.
  2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2 : 795–803.
  3. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia : role of the HIF system. Nat Med 2003; 9 : 677–84.
  4. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73 : 931–4.
  5. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996; 56 : 172–81.
  6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 : 2335–42.
  7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 2006; 355 : 2542–50.
  8. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357 : 2666–76.
  9. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma : CALGB 90206. J Clin Oncol 2008; 26 : 5422–8.
  10. Halimi JM, Azizi M, Bobrie G, et al. Vascular and renal effects of antiangiogenic therapy. Nephrol Ther 2008; 4 : 602–15.
  11. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25 : 4722–9.
  12. Hunt S. Technology evaluation : IMC-1C11, ImClone systems. Curr Opin Mol Ther 2001; 3 : 418–24.
  13. Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun 2006; 345 : 438–45.
  14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355 : 1419–31.
  15. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin®) treatment of proliferative diabetic retinopathy complicated by vitrous hemorrhage. Retina 2006; 26 : 275–8.
  16. Lainer DT, Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 2005; 14 : 1–17.
  17. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97 : 512–23.
  18. Shen J, Vil MD, Zhang H, et al. An antibody directed against PDGF receptor beta enhances the anti-tumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 2007; 357 : 1142–7.
  19. Javerzat S, Auguste P, Bikfalvi A. The role of Fibroblast Growth Factor in vascular development. Trends Mol Med 2002; 8 : 483–9
  20. Shimada N, Ishii T, Imada T, et al. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependant mouse mammary tumors in vivo. Clin Cancer Res 2005; 11 : 3897–904.
  21. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37 : 19–29.
  22. Tuxhorn JA, Mac Alhany SJ, Yag F, et al. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002; 62 : 6021–5.
  23. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277 : 55–60.
  24. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of Angiopoietin-2.Cancer Cell 2004; 6 : 507–16
  25. Delbaldo C, Raymond E, Vera K, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin®), a humanized monoclonal antibody against alphaVbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008; 26 : 35–43.
  26. Halin C, Rondini S, Nilsson F, et al. Enhancement of the antitumor activity of Interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002; 20 : 264–9.
  27. Galaup A, Germain S. Blocking PlGF, a future in anti-angiogenic therapy ? Med Sci (Paris) 2008; 24 : 459–62.
  28. Escudier B, Gross-Goupil M. Revolution in treatment of renal carcinoma : molecular rational and clinical approach. Med Sci (Paris) 2008; 24 : 697–9

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.